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ABSTRACT 
Amongst the entire potential spectrum 
of expansion of the engineering 
sciences as an omnipresent field, we 
might point out the studies of drugs, 
applied pharmacology, as a good 
candidate for receiving attention. The 
common problematic encountered in the 
literature faced by the industry of drugs 
is the high cost for drug development 
and systematic approaches are 
demanded. On the hope to bring the 
discussions to engineering’s territory, 
we borrow several insights from 
mathematical modeling; it is presented a 
simple case study, tumor treatment 
using optimal control, we shall see that 
it is possible with simple tools already 
standard in engineering to design an 
optimal regimen for the tumor therapy, 
given that the tumor respects our model. 
On the example presented, we shall see 
that tools already part of (industrial) 
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production engineering, with exception 
of optimal control theory, is enough for 
getting insights. The ideas discussed 
herein could diminish the cost of drug 
development if properly extended. As 
any endeavor, we have challenges, such 
as to gain the credibility necessary for 
really using those models in the 
academy and industry.  
Key words: Computer Models, 
Pharmacology, Drug Therapy, 
Neoplasms.   
 
RESUMO 
 Entre todo o espectro de expansão das 
engenharias como um campo 
onipresente, é possível citar o estudo de 
medicamentos, de forma mais 
específica farmacologia aplicada, como 
um campo interessante em ser 
considerado. A problemática encontrada 
na literatura enfrentada pela indústria de 
fármacos jaz no alto custo no 
desenvolvimento de novos 
medicamentos, o que torna necessário o 
desenvolvimento de procedimentos 
científicos.  Baseando-se no ponto de 
vista dos autores, de forma alguma a 
proposta considerada feri a busca da 
engenharia de produção como campo 
bem definido. Na tentativa de trazer a 
discussão para o território da 
engenharia, usa-se algumas ideias da 
área de modelagem matemática; um 
estudo simples de tratamento de câncer. 
Mostra-se que com ferramentas já 
presentes na engenharia de produção, 
com exceção de controle ótimo e 
biomatemática, novas ideias podem ser 
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geradas. A discussão apresentada pode 
ser usada para diminuir o custo do 
desenvolvimento de medicamentos se 
aplicado de forma apropriada. Como 
toda teoria, uma busca de consolidar a 
aplicação é necessária, tanto na 
academia quanto na indústria.  
Descritores. Simulação por 
Computador, Farmacologia, 
Quimioterapia, Neoplasias.   
 
RESUMEN 
 Entre todo el espectro potencial de 
expansión de la ingeniería como un 
campo omnipresente, podría señalarse 
los estudios de medicamentos. La 
problemática común encontrada en la 
literatura científica a la que se enfrenta 
la industria es el alto costo para el 
desarrollo de medicamentos y existe la 
necesidad de implementar enfoques 
sistemáticos. En la esperanza de llevar 
las discusiones al territorio de la 
ingeniería, tomamos prestados 
conceptos de la modelización 
matemática; se presenta un estudio de 
caso simple, el tratamiento de tumores 
mediante un control óptimo, veremos 
que es posible con herramientas 
sencillas ya estándar en la ingeniería 
para diseñar un régimen óptimo para la 
terapia de tumores. En el ejemplo 
presentado, veremos que las 
herramientas que ya forman parte de la 
ingeniería industrial, con excepción de 
la teoría de control óptimo, son 
suficientes para conseguir nuevas 
perspectivas. Las ideas discutidas en 
este documento podrían disminuir el 
costo de desarrollo de nuevos 
medicamentos. Como en cualquier 
investigacion, tenemos desafíos, como 
obtener la credibilidad necesaria en la 
academia y la industria. 
Descriptores. Simulación por 
Computador, Farmacología, 
Quimioterapia, Neoplasias.   
1. INTRODUCTION  
 In engineering sciences, the 
concept of ‘model’ can signify model in 
the sense of mathematics, or even a 
‘virtual reality,’ such as it can be built 
in Arena®, something somehow more 
flexible
5
; it is worth noting that in 
pharmacokinetics we have several 
models extremely similar in 
methodological procedures, see
(1)
 for 
more details; as an example see the 
software Modelica® or COPASI®6. 
However, nowadays, we have models in 
medicines quite similar to those models 
applied in engineering for decades; an 
interesting accounting for the most 
important moments of medicine and 
biology can be found in the 
documentaries by Nye
(2-3)
. We will 
discuss this on the sphere of 
pharmacokinetics and 
pharmacodynamics; in general referred 
to as 
pharmacokinetic/pharmacodynamic 
modeling, PK/PD models for short. For 
instance, this is a common practice in 
operations research to observe an 
industrial plant for months, collecting 
data, and then building a replica of this 
for studies, this is done in 
pharmacokinetics for studying drugs on 
the so called compartmental and 
noncompartmental models, see 
discussions in
(4-5)
.  
In essence, in this paper we 
demonstrate the branch of applied 
medicine and pharmacology that was 
born in the exact sciences, but it is so 
important in this day and age to the 
medical sciences that it seems it had 
been developed on this ramification of 
sciences
7. We dissert on the “dynamics 
                                                 
5 Attention must be taken regarding model and sample; 
sample can be used to test a model. Further, model here is 
different from model in that sense of "an ideal material", 
which is predominant in biology and medicine, but also 
present in engineering sciences. 
6 The authors are using as reference a summer school 
attended by the first author and the last one, in Como Lake 
(Italy, 2014), Systems Biology and Systems Medicine, 
http://ucbf.lakecomoschool.org/, where several models were 
presented, either using those softwares or other means of 
simulation and modeling. 
7 Usually, this is given the credibility to T. Teorell due to 
works published in 1937, Kinetics of distribution of 
substances administered to the body. 
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of drugs,” namely, pharmacodynamics, 
and on the “kinetics of drug,” namely, 
pharmacokinetics, and implicitly, on the 
“genomics of drug,” namely, 
pharmacogenomics
8
. We shall see that 
pharmacokinetics and 
pharmacodynamics joined suppose to 
give a complete picture of the drug 
workings inside the body, from 
administration to effects. 
Pharmacogenomics is recent, mainly 
due to technology limitations in the 
past, pharmacogenetics, which is 
considered inside pharmacogenomics, is 
older, but had been limited by the 
difficult experiments it requires, such as 
to study twins.  
 On this paper we defend the 
thesis that amongst the spectrum for 
expansion in the engineering science, 
especially industrial (production) 
engineering, is applied pharmacology. 
This is clearly an important bridge to 
important endeavors in the biomedical 
sciences. Here we are not including the 
participation of those professionals on 
the supply chain, for example, which is 
something already somehow common, 
we mean an active participation on the 
development of new drugs using 
models, systematic approaches such as 
it is already done in studies of industrial 
plants. For the reader interested, see
(6)
 
for several discussions on the 
importance of biology to engineering 
sciences, which include this paper as 
special case.      
  The discovery of drugs was 
one of the most important steps in 
science, it gave us a weapon against 
situations that before certainly would 
culminate on deaths; however it came at 
a price, see for instance
(15-16)
 . 
According to
(7)
, the pharmaceutical 
                                                 
8It is of opinion of the authors that those studies could be 
important on the chase of cure of several diseases such as 
AIDS, especially pharmacogenomics. Viruses such as HIV 
(Human Immunodeficiency Virus) had been so difficult to 
defeat mainly due to their peculiarities to attack the body, 
HIV attaches our genome; their host cells are one of the 
most important cells for our defense, called T-cells.     
industry is amongst the most lucrative, 
and this demonstrate surely the 
importance of the discovery. Still in 
accordance with
(7)
, besides all the 
development, we still need quantitative 
and precise approaches to drug 
development. In harmony with
(8)
, 
pharmacokinetic/pharmacodynamic 
models are important for giving us the 
opportunity for getting the answers for 
questions such as How much? How 
long? How often? Further, empirical 
studies had contributed a lot for our 
understanding of drugs, but they had not 
increased our knowledge about drugs in 
a general sense, what is common to 
group of drugs and what is peculiar to a 
smaller group or even a specific drug; 
new ideias such as P4 medicine hold the 
promise to revolutionize on these 
directions. From the viewpoint of new 
products development, this is an 
extremely complex case
9
.  
 The most important problematic 
in the studies of drugs is how to develop 
them efficiently, in cost and delivery in 
time
(5)10
. The difficulties faced by the 
pharmaceutical industry boils down to 
the high costs on developing drugs for 
new diseases, or even some well-
known, but still to be understood in a 
level to nullify it using drugs. The 
referred problem increases the cost of 
the final product, making it difficult the 
access by whom really needs them, 
especially the people with low monthly 
incomings. On this paper we do not 
consider the problematic of legislation 
and ethical issues, something that on its 
own could take a full paper, or even 
more.  
The case study herein considers 
a drug interaction case. Drug interaction 
can be either pharmacokinetic-like or 
pharmacodynamic-like. With 
                                                 
9 In Brazil this is well-known on the issues created since the 
launched of the “genéricos”, cheap drugs, but in theory with 
the same quality as the conventional ones. 
10 As an example, see the development of the vaccine for the 
virus that causes the so well-known and feared disease 
called dengue. See http://agencia.fapesp.br/17988 for more 
details.    
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a pharmacokinetic interaction, one drug 
affects the other's Absorption, 
Distribution, Metabolism, or Excretion, 
ADME for short, we shall discuss here 
these terms. In 
a pharmacodynamic interaction, two 
drugs have additive (“positive”) or 
antagonistic (“negative”) effects. The 
model presented here is a case of 
pharmacokinetic interaction; a 
pharmacodynamic case can be created 
by a simple change of the dynamics, but 
not discussed here. Further, we give a 
simple example of a 
pharmacokinetic/pharmacodynamic 
model, PK/PD models for short. This 
paper can be decomposed into two 
boxes: the algorithm for optimal 
regimen, based upon optimal control 
theory; and the model for tumor 
growth
11
. For future improvement, 
which is really needed, we might 
improve the boxes isolated, either 
provide a better model for PD/PK or 
provide better optimal control 
methodologies.  
 On the next section we shall 
present the basics of applied 
pharmacology, we intend a writing that 
could be interesting and easy for 
beginnings on the area, in special 
engineers, students for example, looking 
for new areas for investigation, areas 
that surely will be important in the 
future. We try to demonstrate the 
common challenges to any endeavor on 
that direction. Then we present a case 
study, tumor therapy, with the objective 
to transfer the issues to engineering 
grounds, the choice is merely the 
authors’ inclinations.  And, finally, we 
finish up the paper with conclusions and 
final remarks. Following, we present the 
                                                 
11 Using as reference the summer school attented by the first 
author “Mathematical Models and Methods for Living 
Systems”, CIME-Foundation and CIRM, Levico Terme, 
2014, Italy, the model discussed here is not the state of the 
art, it is more didactic than else. For instance, some modern 
models divide the tumor mass into three regions forming a 
sphere or circle in 2D: dead tissue (center), normal or low 
infected tissue (ring), and outer region, which represent the 
attacking region. Further discussions will be omitted.   
references, which indeed is a poor list 
for the readers interested, many more 
can be found given the importance of 
the topics nowadays.  
 
2. DYNAMICS AND KINETICS OF 
DRUGS 
Dynamics of drugs 
(pharmacodynamics) might be defined 
as “what the drugs do to the body,” 
whereas the kinetics of drugs 
(pharmacokinetics) can be defined as 
“what the body does the drugs;” this can 
be used as thumb rule.  The third related 
field is not discussed here, but 
pharmacogenomics, which includes 
pharmacogenetics, can be defined “as 
what genetics make to the drugs and 
vise-verse.” A way to see it clearly the 
subtle differences between 
pharmacokinetics and 
pharmacodynamics is recollecting that 
‘kinetics’ is related to motions, without 
wondering the forces that cause it, 
whereas ‘dynamics’ is related to 
interactions, forces that generate 
motion. It must be pointed that recipes 
always help, but being aware of 
limitations of recipes is a good strategy. 
For instance, the absorption process, in 
general associated to pharmacokinetics, 
might be influenced by 
pharmacodynamics as well, or even 
pharmacogenomics given that several 
people has poor absorption to some 
substances and high absorptions to 
others, not taking into account this 
information can end up on inefficient 
treatment or even toxicity. Divisions 
within science, namely, “divide and 
conquer”, are always motivated by 
future unification. The most important 
models are called 
Pharmacokinetics/Pharmacodynamics 
models, PK/PD models for short. In 
theory, PD/PK models should endow us 
with a complete picture of drug 
administration, an unification between 
pharmacokinetic and pharmacodynamic 
models.  
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One way to draw the line 
between the fields is dividing the whole 
process of drug administration and 
sojourn inside the body into: Dose (D), 
Concentration (C), Effect (E); this can 
be seen as three boxes (state spaces), by 
mass conservation, the drug can only be 
on one of the boxes. PK Models strives 
to comprehend what is happening 
mathematically from the administration 
until the drug concentration increase on 
the site of actions, as we shall see, 
unfortunately the best we can achieve is 
measuring the blood plasma 
concentration, while PD models take 
over the task from the increase in 
concentration to effect. Given that we 
target a single model, we can create the 
PK/PD models, that is, given an 
administration profile (for instance, one 
dose daily), we must have a predictive 
model; the advantage of those models is 
that given that we have a reliable model, 
we can create non-evasive systems for 
real-time treatments. A typical graph for 
pharmacokinetics is Time (x-axis) vs. 
Concentration (y-axis), and for 
pharmacodynamics, Concentration vs. 
Effect. Mathematical models are so 
chased because they make possible 
automation, standardization, and 
optimization. A typical equation for 
PK/PD models is on the template 
presented below.  
 
PK models include studies on 
the steps of: absorption, distribution, 
metabolism, and elimination, ADME 
for short. PD models are more recent 
once they require studies on the level 
that just with the support of current 
technologies we could probe such as 
molecular interactions.   Further, 
example of PD models includes models 
for drug-receptor interactions, study the 
receptors interactions, or finding the 
right receptors for a new drug. See 
figure 1 for a schematic view.  
 
3. CHALLENGES    
 In simple terms, the following 
challenges are common in 
pharmacology, that is, for building up 
PD/PK models: 1) Input and Output 
routes: bearing in mind that we desire 
to “control something” such as the 
number of cancer cells in a patient, we 
must figure it out the best way to feed 
the system. Further, in other to build 
laws for the system, we must 
understand how the input is processed 
and eliminated, the routes used to 
eliminate the introduced substances; 2) 
Target not accessible: on the majority 
of the cases, the site of action are out of 
access either for administration or 
measurements, and we must somehow 
delivery the drug to the correct place; 3)  
Effect Measurements: given that we 
have done the treatment properly, we 
must accompain (monitor), and this 
might be another challenge, find what to 
measure; 4) Side Effects: given that we 
cannot have direct access to the site of 
action and our blood “is in constant 
movement” due to the circulatory 
system, we must be aware of side effect, 
which is not simple to predict.    
 
a) 
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b) 
FIGURA 1 – “Frontiers” between pharmacokinetics and pharmacodynamics and the phases for the 
pharmacokinetics. a) depicts the pharmacokinetic phases for the drug administration; b) is the frontiers between 
pharmacokinetics and pharmacodynamics.  ‘C’ stands for concentration, and the subscripts ‘max’ for the maximum 
concentration. In a) the first phase is absorption, the second is distribution and metabolism and the third is 
elimination. Several parameters used in simulations are estimated from those graphs. The metabolism phase cannot 
be differentiated from the distribution just using this kind of graphs. Source: own elaboration. 
 
3.1 Input and Output Routes  
 As any system with potential 
ways to be influence or even control, 
the human body possesses several input 
and output routes. Basically, we have 
two groups of input routes: 
intravascular and extravascular. 
Intravascular signify that the drug were 
administrated directly on the blood such 
as veins, whereas extravascular is 
reserved to routes such as oral, that is, 
the drug must pass through the 
absorption process. It is a well-known 
trick to eliminate the complexity of drug 
studies to make it in intravascular way 
for getting ride of the absorption, 
several parameters is estimated this 
way, they are the same for extravascular 
administration.  
 The form chosen to administer 
the drug is vital as well. The most 
theoretical approach is called bolus 
administration
12
, bolus dose. 
Mathematically this is represented by 
the Dirac Function, largely applied in 
mathematics and quantum mechanics 
for representing pulses. The second 
way, much more realistic, is the 
intermittent infusions; in fact this is 
possible as well to cite multiple bolus 
administrations. The advantage of 
                                                 
12 It gives us some nice mathematical tricks such as 
convolution, it can be used to estimate cumulative effect of 
multiple dose in time.   
intermittent infusions
13
 is that the  
concentration does not rise fast as it 
happens with bolus doses, further, the 
concentration starts from zero. Thus, in 
intermittent infusions, the concentration 
grows gradually toward a steady state. 
In the case of bolus doses, in real cases, 
they are administered using a short 
time, shorter than intermittent 
infusions
14
.  
 We have essentially two “output 
doors”, in fact for some cases we have 
three, the lung might be added up, for 
elimination of drugs introduced to the 
body: livers and kidneys
15
. The two 
output routes make use of the blood to 
eliminate the drug. Hence, compartment 
models, see coming sections, just 
assume elimination on the central 
compartment, in general the blood and 
(well perfused tissues) “well-fed” 
tissues.  On the case of a second 
compartment, we call this second one 
peripheral compartment.  
 
 
                                                 
13 Here we reach a problem, why intermittent infusion? A 
second option is continuous infusions. Intermittent  
infusions is more typical for oral administration. Bolus and 
continuous infusions are more typical of intravascular 
administration. The choice here was motivated by the fact 
that intermittent infusion, due to the interval, represents 
more challenge to program.     
14  Seer, 
http://www.uri.edu/pharmacy/faculty/rosenbaum/basicmode
ls for several  simulations  and  discussions.  Last access: 
June, 2014. 
15 This is true for the majority of drugs, except for drug such 
as for anesthetics, volatile drugs, where the lungs starts to be 
important on the elimination process. 
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3.2 Inaccessible Target 
 
 With rare cases, such as skin 
diseases, the region affected by the 
disease is out of access, any access 
would be considered surgical procedure, 
something avoided in several cases, or 
even impossible
16
. Therefore, the 
problematic in drug administration is 
how to efficiently treat a disease giving 
we cannot access the place where it is, 
in several cases such as AIDS or even 
cancer, they are impossible to be 
accessed. See scheme in figure 2. Thus, 
the omnipresent problem in 
pharmacokinetics/pharmacodynamics is 
how to access the site of action of a 
given drug.  
The circulatory system is the 
commonest way used to overcome the 
problem of administrating drugs once it 
runs all of over the body. In the case of 
oral administration, such as pills, we 
have the process of absorption before 
the systemic circulation is reached; see 
that a drug is considered to be inside the 
body just after being completely 
absorbed, in the blood, the absorption 
process is so complex that even after 
overcoming the wall of the intestinal 
tract, the drug still can be “rejected.” 
And on the case of measurements, 
either samples from the blood or the 
substances eliminated such in the urine 
can be used to measure expected results, 
tests adopted in the majority of 
companies. 
                                                 
16 See that the lungs can be directly accessed, or even the 
liver in some therapies. 
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FIGURE 2 – Scheme giving emphasis to the problems encountered when we study drugs administered to the body. 
We show two potential ways: direct on the systemic circulations and by other routes that culminate on the systematic 
circulation.  Source: own elaboration.  
   
3.3 Effect Measurements 
 
 As any area of knowledge, 
measure effects on the treatment of 
diseases is not something always 
straightforward, and something 
creativity is the best that we can do, that 
is, a “movement of art.” In(9) it is 
proposed a physical device, non-
invasive measurement system, based on 
the degradation of a electronic 
polymeric solution for measuring the 
effectiveness of the phototherapy, 
mainly for avoiding continuous blood 
sampling on babies effective by the 
neonatal jaundice. In
(10)
, it is studied an 
intelligence based algorithm using fuzzy 
logic for identifying diabetic patients 
using the electrocardiogram signal. 
These surely represent examples where 
we must make use of alternative 
techniques for overcoming problems of 
measuring the state of human body with 
reference to normal states. Systems for 
measuring response to treatments are in 
general called biometers. Even on 
invasive cases, it might not be obvious 
what to measure, such on the treatment 
of diseases that attack the immune 
system, it might be a good strategy to 
monitor the number of platelets on the 
blood.    
 
3.4 Side Effects  
 Several texts discuss on the 
concept of side affects, toxicity, and 
undesired effects. Here we assume that 
undesired effects and side affects are the 
same. Nonetheless, the concept of 
toxicity is little more delicate. In several 
books about pharmacology the topic is 
treated, nonetheless, toxicity is not 
expected to be a topic since it is not 
what we want, it is studied to be 
avoided. Side affects might emerge 
even if it is applied the drug properly 
and in several cases, this is tolerated, 
such as gaining weight as result of use 
of several drugs. However, toxicity is 
never welcome. For avoiding toxicity, 
but having results on a treatment, the 
concept of therapeutic window is 
widely used. It basically endow us with 
a superior and inferior limits, the former 
shows where we start to expect toxicity 
and the latter where we do not expect 
results at all. A good drug treatment 
must keep the concentration of drug in 
the body within this window. For 
several medications, due to a narrow 
therapeutic window, just intravascular 
administration can be used to keep the 
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concentration on this window, above 
needed concentration for effect, but 
below danger concentrations. Each drug 
possesses a therapeutic window, and it 
can change even from person to person 
using the same drug.   
 
4. COMPARTMENT MODELS 
 
 As other areas in science, studies 
of drugs are done by several models. 
One of the most popular due to 
simplicity and applicability are the ones 
called compartment models. The name 
comes from the fact that the body is 
divided into compartments “seen” by 
the drug. Some drugs after 
administration quickly spread out 
throughout the body, others take time. 
From the viewpoint of engineering, it 
does not represent a new methodology 
once software such Arena®, Umberto®, 
and others have already been applying 
these for a while in an industrial 
framework. In simple language, this is 
just the famous “divide and conquer.” 
On those models, the body is divided 
into compartments that communicate 
among each other. For example, take 
the study of lead, toxic substance, a 
heavy metal. See scheme below. The 
body is divided into blood, bone, and 
soft tissues. There is movement from 
the blood to bones, and coming back. 
Similarly, we have a movement from 
blood to soft tissues, and the return. 
From the blood, the metal can be 
eliminated, thus coming back to 
environment
17
.  
 
 
5. OPTIMAL DRUG 
ADMINISTRATION: TUMOR 
THERAPY
18
 
                                                 
17 The biggest danger of heavy metals is that they “stick” to 
the bones, causing problems in the future of the people that 
had contact with them. A quite common problem used to 
happen in Brazil in the chase for gold, using mercury, 
forbidden by law now, what had not necessary stopped 
completely the problem. 
18
 See for example http://en.wikipedia.org/wiki/Neoplasm, 
last access: June/2014. 
 
 Tumor is a state of the body 
where cells divide (mitosis, multiply) on 
an uncoordinated way. This is a type of 
cancer
18
in some cases.  Tumors might 
be classified as benign, premalignant, 
or malignant (cancer). Cancer is so 
feared for spreading out, invading 
neighboring tissues, tumors 
(premalignant cancer) does not invade 
neighboring tissues. On this section we 
present the simplest model possible to 
build applying the theories presented 
throughout the papers so far. We have 
decided to spend time on such section 
for making the discussions accessible to 
professional for engineering sciences. 
Here we make a typical methodological 
approach in engineering: we have a 
problem, we model the problem, and we 
study it with our model. The model 
presented herein is relatively simple. 
We apply the theory of optimal control 
for the treatment of cancer
19
. Using the 
mentioned theory, we can optimize the 
behavior of a set of differential 
equations, on our case, ordinary 
differential equations.  
The model discussed here was 
published by
(11)
 and studied by
(12-13)
; we 
try to make it better by adding the 
dynamic of the drug.  
 The referred model used on the 
study of treatment of tumor is as 
following: 
                                                 
19 This is worth to pinpoint that the same authors had 
submitted a second paper to this same edition of the periodic 
where optimal control is discussed on the domains of 
operations research. The algorithms and methodological 
procedures are the same, then the reader interested might 
want to consult this paper.   
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Where:  tN   is the growth rate, 
derivative of the unknown function for 
the tumor cells;  tN   is the density of 
tumor cells at time ‘t’, this variable is 
normalized, minimum value close to 
‘0’, small amount of tumor cells, and 
maximum equal 1, maximum tumor 
cells; r  is the “aggressiveness” of the 
tumor;   is the “efficacy” of our 
treatment, “responsiveness” to the 
treatment;  tu  is the control variable. 
The log on the growth term is justified 
bearing in mind that the tumor growth is 
nonlinear.   
See that the first term of the 
differential equation represents a 
‘growth’, a natural process, using a 
dynamics called Gompertz model
20
, and 
the second represent our control by 
means of the treatment. It should be 
pointed out that we can use just this 
equation on the study of optimal control 
applied to tumor therapy and this is 
what is done on
(12)
, but we can do 
better! What about the dynamics of the 
drug? This is what we add here. This is 
motivated by the discussions on this 
paper, in the last sections. Drugs might 
exhibit peculiar behavior and assuming 
that we can control the amount exactly 
of drug that reaches the site might be a 
mistake. As
(12)
 highlights studies of 
drugs is a rich and state of the art field, 
and one of the models lacking are the 
ones that studies multiple drugs taken at 
the same time. That is, models that 
takes into account interactions between 
different drugs; see that the model 
presented here is limited in the sense 
that it is still kinetics, not dynamics, 
models for dynamics are much 
complicate, we skip them. Just to 
provoke these studies on the literature, 
let’s consider an ideal case of two drugs 
                                                 
20 The growth is slow in the beginning and end. With the 
L’Hospital’s Rule, limit theory, and some patience, we can 
show those proprieties, or just plot the graph. 
taken for eliminating this tumor. We 
consider a simple case, the second drug 
just increase the absorption of the first, 
the drug one is the one that really can 
eliminate the tumor. This can increase 
the possibility to maintain the plasma 
concentration within the therapeutic 
window; see that the second drug is 
increasing the absorption, then it should 
eventually increase the concentration 
above the therapeutic window of the 
drug we need to monitor, and this 
exactly the trick of optimal control, the 
optimal control policy will just use what 
is needed given a goal (therapeutic 
window). This is known as 
bioavailability; this is similar when you 
are suggested to take a drug together 
with milk, milk is not a drug, just 
increase the bioavailability of the take 
drug, or even when you are asked to use 
a drug with empty stomach. This type of 
analysis is concern of 
noncompartmental models.  
Noncompartmental models are 
considered easier to use due to several 
reasons such as it does not change from 
individual to individual so much as 
compartment models. See
(5)
 for more 
details.  
We should not let it stay 
unmentioned that the model presented 
here for tumor treatment is merely 
illustrative, we have not conducted 
experiments for creating the model, this 
is a theoretical model. We are motivated 
to apply optimal control for finding the 
best optimal policy for the cancer 
treatment, given that our model is 
correct or at least not too far away from 
what happen in living systems, we omit 
the methodological procedures; see 
second paper submitted to this event by 
the same authors. In simple terms, we 
apply the theory of optimal control, we 
arrive to a system of differential 
equations, and then we apply numerical 
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schemes for integrating differential 
equations for finding the optimal 
control and optimal trajectory for the 
function of the cancer cells. It is not 
redundant to mention that drug only on 
the site of action is wanted, before it can 
achieve the site of action, this must 
achieve the circulatory system. Here for 
simplicity we assume a single-
compartment for the individual-drug 
profile, that is, the concentration of drug 
in the blood stream is instantaneous 
transmitted to the site of action.  The 
model is composed of three differential 
equations: drug 1, drug 2, and cancer 
dynamics. The first equation is for the 
drug one, the one that really matters for 
the tumor treatment: administration 
minus elimination. The second equation 
is similar, but remember that it just 
effects the drug 1 dynamics, alone it is 
meaningless. The third equation is the 
one for cancer cell, just the drug 1 
matters for this dynamics. For modeling 
the interaction of drug 1 and drug 2 we 
make use of the famous Michaelis-
Menten Equation, widely used in 
biochemistry. We apply the treatment 
on the style of intermittent infusions, we 
apply for a while and than we give a 
break. This is repeated for a time 
determined period of time. Below is the 
graph that results from the simulations, 
figure 3. 
 
FIGURE 3 – Simulations for the discontinuous treatment of tumor. The dashed and continuous line simulates the treatment in 
several scenarios. The continuous lines represent variations on the therapy, drug infusion, compared to the breaks, non drug at all. 
On the dashed green line we simulate the case of increasing the importance of minimizing the cancer cells compared to the costs and 
side effects, weight here is similar to problems in operations research where preferences are entered the model, or even penalty 
values. We have used the same weight – impact for using – in the minimization process for the drugs. We have used a very bad case 
0.975/1 – initial value/maximum possible tumor mass – well-advanced. The x-axis was discretized for numerical simulations, ‘step’ 
means one unit of this discretization. 2000 steps (20 units of time) comprise a whole treatment (therapy plus rest). y-axis is the 
tumor cell density  ‘Rest’ means that all the control is “turned off” and we let the dynamics of the cancer to evolve free. An 
interesting improvement would be to model the body response to the lack of medication after the treatment had started. By ‘just 
therapy’ it is meant that we do not stop from one infusion to another, the wave-like behavior is a result of the tumor “trying to come 
back.”  Source: own elaboration. 
On the case just presented, we 
have showed that we can calculate the 
optimal therapy for the treatment of an 
ideal tumor, given that we have found a 
proper dynamical model. We know that 
real cases are full of surprises, contra-
reactions is quite common. Some 
models for control that has been gaining 
certain respect are the ones that comes 
form computational intelligence
(14)
, 
something sadly we must skip. 
 
6. CONCLUSIONS AND FINAL 
REMARKS  
 
 On this paper, we have 
discussed on the possible impact of 
studies on drugs in engineering 
sciences. Furthermore, this works might 
be faced as extension of
(6)
, but now on 
Revista Eletrônica Gestão & Saúde ISSN: 1982-4785 
Pires JG, Maggio R, Manes C, et al. Engineering sciences: pharmacokinetics and pharmacodynamics as an inter…  
 Revista Eletrônica Gestão & Saúde. Vol. 6 (Supl. 2).  Abril, 2015 p. 1055-67 1066 
 
the domain of pharmacology instead of 
biology.   
On the hope to bring the studies 
to engineering grounds, we have used 
mathematical modeling. We have 
analyzed the case of studying 
(designing) the therapy of an ideal 
tumor using a dynamics taken from the 
literature and mathematical models 
derived from optimal control theory for 
chasing a best policy given a set of 
information of an ideal cancer. On the 
discussed case we have showed that 
with tools already present in 
engineering sciences, such as industrial 
engineering, we can gain insights 
regarding the problem. We have used an 
external methodology from production 
called optimal control, but discussed on 
a second paper by the same authors on 
the context of industrial (production) 
engineering
(17)
. This can be seen from 
reality and from the literature that the 
pharmaceutical industry are one of the 
most complex, lucrative, and high costs 
for developing and designing new 
products. Take as example the problem 
with cheap drugs in Brazil, several 
programs had started, but it had not 
been easy to keep up the promises.   
Regarding the simulations, 
caution must be placed, the dynamic 
used is ideal, better models are being 
proposed everyday, the same way in 
statistics a good inference model can 
give wrong results if applied in bad 
sampling, even the best optimal control 
technique cannot yields something 
correct if not fed with a proper dynamic.  
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